Related Experiment Video
Updated: Mar 26, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.8K
Type 2 Diabetes and ADP Receptor Blocker Therapy
Matej Samoš1, Marián Fedor2, František Kovář1
1Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia.
Journal of Diabetes Research
|January 30, 2016
Summary
Patients with type 2 diabetes (T2D) exhibit impaired responses to clopidogrel, a common antiplatelet medication. This high on-treatment platelet reactivity increases the risk of blood clots and ischemic events in T2D patients.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes (T2D) is linked to hemostatic abnormalities, increasing thrombosis risk.
- T2D is associated with reduced effectiveness of clopidogrel, a widely used antiplatelet drug.
- High on-treatment platelet reactivity (HTPR) to clopidogrel correlates with ischemic events.
Purpose of the Study:
- To review current understanding of interactions between T2D and ADP receptor blocker therapy.
- To explore the connection between T2D and impaired antiplatelet response to clopidogrel.
- To discuss the implications of HTPR in patients with type 2 diabetes.
Main Methods:
- Literature review of studies investigating T2D and clopidogrel response.
- Analysis of data on platelet reactivity in diabetic patients on antiplatelet therapy.
- Synthesis of evidence linking T2D, HTPR, and ischemic events.
Main Results:
- Patients with T2D demonstrate significantly higher residual platelet reactivity on clopidogrel.
- T2D patients are disproportionately represented in groups experiencing HTPR.
- Impaired clopidogrel response in T2D contributes to increased thrombotic risk.
Conclusions:
- T2D adversely affects antiplatelet therapy efficacy, particularly with clopidogrel.
- Understanding T2D-clopidogrel interactions is crucial for managing ischemic risk.
- Further research is warranted to optimize antiplatelet strategies in type 2 diabetes.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:36Carbohydrate Metabolism
15.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
15.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K